Prevention of Deep-Vein Thrombosis After Total Knee Arthroplasty in Asian Patients COMPARISON OF LOW-MOLECULAR-WEIGHT HEPARIN AND INDOMETHACIN
|
|
- Francis Spencer
- 5 years ago
- Views:
Transcription
1 136 COPYRIGHT 2004 BY THE JOURNAL OF BONE AND JOINT SURGERY, INCORPORATED Prevention of Deep-Vein Thrombosis After Total Knee Arthroplasty in Asian Patients COMPARISON OF LOW-MOLECULAR-WEIGHT HEPARIN AND INDOMETHACIN BY CHING-JEN WANG, MD, JUN-WEN WANG, MD, LIN-HSIU WENG, MD, CHIA-CHEN HSU, MD, CHUNG-CHENG HUANG, MD, AND PAO-CHU YU, MD Investigation performed at the Departments of Orthopedic Surgery and Diagnostic Radiology, Chang Gung Memorial Hospital, Kaohsiung, Taiwan Background: A prospective clinical study was performed to compare the efficacy of low-molecular-weight heparin and indomethacin for the prevention of deep-vein thrombosis after total knee arthroplasty in Asian patients. Methods: One hundred and fifty patients undergoing total knee arthroplasty were randomly divided into three groups. One group consisted of fifty-one patients who received no prophylaxis with an anticoagulant (the control group), one consisted of fifty patients who received the low-molecular-weight heparin Fraxiparine (the Fraxiparine group), and the third consisted of forty-nine patients who received indomethacin (the indomethacin group). Bilateral ascending venography was performed preoperatively and at five, six, or seven days postoperatively. A third venogram was made at three months for patients who had had a deep-vein thrombosis. Results: The prevalence of deep-vein thrombosis was 71% in the control group, 50% in the Fraxiparine group (p = 0.042), and 45% in the indomethacin group (p = 0.011). Only 28% of the deep-vein thromboses were symptomatic, and there were no pulmonary emboli. Conclusions: Compared with no prophylaxis, Fraxiparine and indomethacin significantly lowered the prevalence of deep-vein thrombosis after total knee arthroplasty. Prophylaxis against deep-vein thrombosis in the Asian population appears to be warranted. Level of Evidence: Therapeutic study, Level I-1a (randomized controlled trial [significant difference]). See Instructions to Authors for a complete description of levels of evidence. Several recent studies have demonstrated that the prevalence of deep-vein thrombosis after total knee arthroplasty in the Asian population is similar to that in the Western population 1,2. However, the locations of the thromboses in Asian patients have differed, with a predominance of distal clots (in the calf) and very few proximal clots (in the thigh or pelvis) or pulmonary emboli 2. Therefore, the risks of deep-vein thrombosis after total knee arthroplasty have not been fully appreciated and the importance of prophylaxis against this complication has not been emphasized in Asian countries. In contrast to the situation in Western countries, where routine prophylaxis against deep-vein thrombosis is standard practice after total joint replacement 3-9, pharmaceutical prophylaxis against deep-vein thrombosis is not routine in most hospitals in the East Therefore, prophylactic strategies after major orthopaedic procedures remain controversial in the East 4, Indomethacin is one of the most commonly prescribed nonsteroidal anti-inflammatory drugs for postoperative analgesia as well as for treatment of arthritic knees in Taiwan. We are not aware of any reports on the efficacy of indomethacin for the prevention of deep-vein thrombosis after total knee arthroplasty. We speculated that, while it is being used as an analgesic, indomethacin might also lower the prevalence of deep-vein thrombosis through its ability to decrease platelet aggregation. Low-molecular-weight heparin is the most commonly used pharmaceutical agent for prophylaxis against deep-vein thrombosis in North America and Europe ; however, its efficacy in the Asian population has not been established, to our knowledge 16. The purpose of this prospective clinical study was to compare the efficacy of a low-molecularweight heparin (Fraxiparine) and that of indomethacin for the prevention of deep-vein thrombosis after total knee arthroplasty in an Asian population.
2 137 TABLE I Prevalence and Location of Deep-Vein Thrombosis Seen on Venograms at Five, Six, or Seven Days Postoperatively Control Fraxiparine Indomethacin Total No. of patients Deep-vein thrombosis No. (%) of patients 36 (71%) 25 (50%) 22 (45%) 83 (55%) Compared with control group Compared with Fraxiparine group Location of deep-vein thrombosis Calf veins (94%) Popliteal vein (6%) Femoral vein Iliac vein Pulmonary embolism Symptomatic deep-vein thrombosis No. (%) of all thromboses 15 (42%) 4 (16%) 4 (18%) 23 (28%) Compared with control group Compared with Fraxiparine group Materials and Methods he institutional review board of our hospital approved the Tstudy, and all patients provided informed consent to participate in it. The exclusion criteria included recent thromboembolic disease, a history of a coagulopathy including thrombocytopenia, a history of allergy to iodine, and a technical failure in the performance of venography. From July 2001 to June 2002, 150 patients (118 women and thirty-two men) scheduled to undergo total knee replacement were recruited. The average age (and standard deviation) of the patients was 66 ± 9 years (range, thirty-two to eighty-two years), the average body weight was 67 ± 10 kg (range, 45 to 100 kg), and the average body height was ± 7.6 cm (range, 139 to 179 cm). Seventy-two of the total knee arthroplasties were performed on the right side and seventy-eight, on the left side. Patients were randomly divided into three groups according to the admission schedules. One group consisted of fifty-one patients who received no prophylaxis with an anticoagulant (the control group), one consisted of fifty patients who received Fraxiparine (the Fraxiparine group), and one consisted of fortynine patients who received indomethacin (the indomethacin group). The dosage of Fraxiparine, which was based on the patient s body weight, ranged from 1900 IU, or 0.2 ml, to 3800 IU, or 0.4 ml, per day and was given subcutaneously from the day before the surgery to the day of discharge from the hospital. The dosage of indomethacin was 25 mg given orally twice daily starting on the day before the surgery and continuing until the day of discharge from the hospital. The indomethacin was given in suppository form to patients with gastrointestinal intolerance. The preoperative workup included a complete blood-cell count, coagulation and chemistry profiles, electrocardiography, chest radiographs, and radiographs of the affected knee. Two orthopaedic surgeons (C.-J.W. and J.-W.W.) performed all of the operations with tourniquet control and with the patient under either general or spinal anesthesia. One type of knee prosthesis (Advantim; Wright Medical Technology, Arlington, Tennessee) was used in all patients, and all components were cemented. Intravenous cefamezine was given to all patients for prophylaxis against infection. All patients were managed postoperatively with the same protocol, which included bedside continuous passive motion, physiotherapy with partial weightbearing on the operatively treated limb, and range-of-motion, quadriceps, and hamstring exercises. In addition, patients were encouraged to perform calf pump exercises bilaterally. Bilateral ascending venography was performed within one week preoperatively and at five, six, or seven days postoperatively. If the venogram showed positive findings for deepvein thrombosis, then a repeat venographic study on the affected lower limb was performed at three months. Two radiologists who were blinded to the nature of the study interpreted the results of the venograms. The criteria for the diagnosis of deep-vein thrombosis included an intraluminal filling defect, abrupt termination of the opaque contrast column, and nonfilling of the deep veins proximal to the knee. Any difference in opinion between the radiologists was discussed to reach a consensus before the final report was made. Clinical symptoms suggestive of deep-vein thrombosis, including pain and swelling of the limb, calf tenderness, skin discoloration, venous engorgement, enlargement of the girth of the calf or thigh, the Homans sign, and temperature elevation, were sought daily. A deep-vein thrombosis was defined as symptomatic when symptoms that required treatment developed in a patient with a positive venogram. Each symptomatic
3 138 deep-vein thrombosis was graded clinically as mild, moderate, or severe. Patients with severe symptoms were treated initially with intravenous heparin until the symptoms decreased and then with oral warfarin until the symptoms subsided. Patients with mild or moderate symptoms were treated with aspirin. When symptoms suggestive of pulmonary embolism, including chest pain, difficulty breathing, or hemoptysis, developed, additional studies, including arterial blood gas measurement, a chest radiograph, and a perfusion lung scan, were performed. The data for the Fraxiparine and indomethacin groups were compared statistically with those for the control group and with each other with use of the Mann-Whitney test. Significance was set at p < Results enographic studies were performed preoperatively on eighty- patients (eighty-three operatively treated and eighty- Vthree one untreated lower limbs, with two technical failures in the untreated limbs). There were five preoperative deep-vein thromboses in the calf, including four on the operatively treated side and one on the untreated side, but none of the thromboses were symptomatic. The overall prevalence of preoperative deep-vein thrombosis was 3% (five of 164), with 5% (four) in the eighty-three operatively treated limbs and 1% (one) in the eighty-one untreated limbs. One hundred and fifty patients had venographic studies performed in the first postoperative week. A positive deep-vein thrombosis was noted in eighty-three (55%) of the 150 operatively treated limbs and twenty-one (14%) of the untreated limbs. Ninety-four percent of the eighty-three deep-vein thromboses in the operatively treated limbs were in the calf veins, 6% were in the popliteal vein, and none were in the femoral or iliac vein. Twenty-eight percent (twenty-three) of the eighty-three clots in the operatively treated limbs were symptomatic, and none of the clots in the untreated limbs were symptomatic. The prevalences and locations of the deep-vein thromboses in the operatively treated limbs are summarized in Table I. The prevalence of deep-vein thrombosis was 71% (thirty-six of fifty-one) in the control group, 50% (twenty-five of fifty) in the Fraxiparine group (p = 0.042), and 45% (twenty-two of forty-nine) in the indomethacin group (p = 0.011). There was no significant difference, with the numbers available, between the Fraxiparine and indomethacin groups with regard to the prevalence of deep-vein thrombosis (p = 0.616). Symptoms were associated with 42% (fifteen) of the thirty-six deep-vein thromboses in the control group, 16% (four) of the twentyfive in the Fraxiparine group (p = 0.035), and 18% (four) of the twenty-two in the indomethacin group (p = 0.067). There was no significant difference, with the numbers available, between the Fraxiparine and indomethacin groups with regard to the prevalence of deep-vein thromboses that were symptomatic. The five patients with silent deep-vein thrombosis preoperatively also had a positive venogram postoperatively. The size of the postoperative deep-vein thrombosis was the same as the preoperative thrombosis in four patients and was slightly larger in one, but none were clinically symptomatic. Severe symptoms developed in association with the deep-vein thrombosis in fifteen patients, including nine in the control group, two in the Fraxiparine group, and four in the indomethacin group. Of the fifteen patients, twelve (seven in the control group, two in the Fraxiparine group, and three in the indomethacin group) were initially treated with intravenous heparin for three to five days until the symptoms decreased and then with oral warfarin for four to ten weeks until the symptoms subsided. The dosage of warfarin was monitored by measuring the prothrombin time and international normalization ratio. A prolonged international normalization ratio was found in four patients, but none had a bleeding complication. The remaining three patients, including two in the control group and one in the indomethacin group, were treated with a therapeutic dose of Fraxiparine for seven to ten days. No bleeding complications were noted. Eight patients, TABLE II Prevalence and Location of Deep-Vein Thrombosis Seen on Venograms at Three Months Control Fraxiparine Indomethacin Total No. of patients Deep-vein thrombosis No. (%) of patients 9 (25%) 7 (28%) 3 (15%) 19 (23%) Compared with control group Compared with Fraxiparine group Location of deep-vein thrombosis Calf veins Popliteal vein Femoral vein Iliac vein Pulmonary embolism Symptomatic deep-vein thrombosis (no. [%] of all thromboses) 1 (11%) 1 (14%) 1 (33%) 3 (16%)
4 139 including five in the control group, two in the Fraxiparine group, and one in the indomethacin group, were treated for mild or moderate symptoms with aspirin (325 mg twice daily) until the symptoms subsided, which occurred in fourteen to forty-nine days. Three patients complained of chest pain and a tight sensation in the chest while breathing, but none had hemoptysis, and perfusion lung scans revealed a low probability for pulmonary embolism in all patients. The symptoms decreased without anticoagulation therapy. Of the eighty-three patients who had a positive deepvein thrombosis postoperatively, eighty-one (thirty-six in the control group, twenty-five in the Fraxiparine group, and twenty in the indomethacin group) underwent a third venographic study at three months. The remaining two patients refused repeat venography. Nineteen of those repeat studies, including nine in the control group, seven in the Fraxiparine group, and three in the indomethacin group, revealed a deepvein thrombosis. All of the thromboses were distal (in the calf veins). At three months, the prevalence of deep-vein thrombosis in patients who had had a deep-vein thrombosis postoperatively was 23% (nineteen of eighty-one) overall, with a prevalence of 25% (nine of thirty-six) in the control group, 28% (seven of twenty-five) in the Fraxiparine group (p = 0.879), and 15% (three of twenty) in the indomethacin group (p = 0.610). There was no significant difference, with the numbers available, between the Fraxiparine and indomethacin groups (p = 0.690). The prevalences and locations of the deep-vein thromboses at three months are summarized in Table II. Of the nineteen deep-vein thromboses, three (one in each group) were symptomatic. These three cases were treated with acetaminophen until the symptoms subsided, with the duration of treatment ranging from two to eight weeks. There were no systemic complications related to the venography; however, one patient had transient chills. Local complications included pain and numbness of the foot in one patient and leakage of contrast material in another. Discussion effect of low-molecular-weight heparin with regard to Tthe prevention of deep-vein thrombosis in an Asian population has not been established, to our knowledge. The results of this study showed that Taiwanese patients who received prophylaxis with Fraxiparine had significantly fewer deep-vein thromboses and symptomatic deep-vein thromboses after total knee arthroplasty than did the control group. Therefore, lowmolecular-weight heparin (Fraxiparine) appears to be effective for prophylaxis against deep-vein thrombosis after total knee arthroplasty in an Asian population. Conventional nonsteroidal anti-inflammatory drugs, including indomethacin, inhibit platelet aggregation, prolong bleeding time, and decrease the level of serum thromboxane B 2 7,8. Indomethacin is a commonly prescribed drug primarily used for analgesia postoperatively and as an anti-inflammatory drug for degenerative arthritis. Indomethacin also has the potential for preventing deep-vein thrombosis by decreasing platelet aggregation 7,8. The results of this study showed that indomethacin significantly lowered the prevalence of deep-vein thrombosis (p = 0.011) and lowered the prevalence of symptomatic deep-vein thrombosis (p = 0.067) after total knee arthroplasty. The efficacy of indomethacin for the prevention of deep-vein thrombosis after total knee arthroplasty was comparable with that of Fraxiparine in our study group. Therefore, indomethacin appears to have the additional benefit of preventing deep-vein thrombosis while providing postoperative analgesia. The administration of indomethacin is convenient and relatively inexpensive. In Western countries, the reported prevalence of deepvein thrombosis after total knee arthroplasty has been consistently high, especially in patients without anticoagulation prophylaxis 23. Similar findings were reported in Asian populations when venography was performed 1,2,10 ; however, the rate of proximal clots in the thigh and pelvis has been very low in the Asian population 2. This study showed that the prevalences of deep-vein thrombosis and symptomatic deep-vein thromboses were higher in the control group than in the patients receiving prophylaxis with either Fraxiparine or indomethacin. However, neither Fraxiparine nor indomethacin totally prevented deep-vein thrombosis. In conclusion, low-molecular-weight heparin (Fraxiparine) and indomethacin significantly lower the prevalence of deep-vein thrombosis after total knee arthroplasty in an Asian population. There were no pulmonary emboli or deaths in our study, but the series was small. There was a higher prevalence of deep-vein thrombosis, and patients were frequently symptomatic, without pharmaceutical prophylaxis. Ching-Jen Wang, MD Jun-Wen Wang, MD Lin-Hsiu Weng, MD Chia-Chen Hsu, MD Chung-Cheng Huang, MD Pao-Chu Yu, MD Departments of Orthopedic Surgery (C.-J.W., J.-W.W., L.-H.W., and C.-C. Hsu) and Diagnostic Radiology (C.-C. Huang and P.-C.Y.), Chang Gung Memorial Hospital, 123 Ta-Pei Road, Niao-Sung Hsiang, Kaohsiung 833, Taiwan. address for C.-J. Wang: w281211@adm.cgmh.org.tw. The authors did not receive grants or outside funding in support of their research or preparation of this manuscript. They did not receive payments or other benefits or a commitment or agreement to provide such benefits from a commercial entity. No commercial entity paid or directed, or agreed to pay or direct, any benefits to any research fund, foundation, educational institution, or other charitable or nonprofit organization with which the authors are affiliated or associated. References 1. Dhillon KS, Askander A, Doraismay S. Postoperative deep-vein thrombosis in Asian patients is not a rarity: a prospective study of 88 patients with no prophylaxis. J Bone Joint Surg Br. 1996;78: Wang CJ, Wang JW, Chen LM, Chen HS, Yang BY, Cheng SM. Deep vein thrombosis after total knee arthroplasty. J Formos Med Assoc. 2000;99:
5 Hodge WA. Prevention of deep vein thrombosis after total knee arthroplasty. Coumadin versus pneumatic calf compression. Clin Orthop. 1991;271: Kakkar VV, Howe CT, Flanc C, Clarke MB. Natural history of postoperative deep-vein thrombosis. Lancet. 1969;2: Lotke PA, Steinberg ME, Ecker ML. Significance of deep venous thrombosis in the lower extremity after total joint arthroplasty. Clin Orthop. 1994;299: Maynard MJ, Sculco TP, Ghelman B. Progression and regression of deep vein thrombosis after total knee arthroplasty. Clin Orthop. 1991;273: McKenna R, Bachmann F, Kaushal SP, Galante JO. Thromboembolic disease in patients undergoing total knee replacement. J Bone Joint Surg Am. 1976;58: McKenna R, Galante J, Bachmann F, Wallace DL, Kaushal PS, Meredith P. Prevention of venous thromboembolism after total knee replacement by highdose aspirin or intermittent calf and thigh compression. Br Med J. 1980; 280: Merli GJ. Duration of deep vein thrombosis and pulmonary embolism prophylaxis after joint arthroplasty. Med Clin North Am. 2001;85: Kim YH, Kim JS. Incidence and natural history of deep-vein thrombosis after total knee arthroplasty. A prospective, randomised study. J Bone Joint Surg Br. 2002;84: Kim YH, Kim VE. Factors leading to low incidence of deep vein thrombosis after cementless and cemented total knee arthroplasty. Clin Orthop. 1991; 273: Kim YH, Suh JS. Low incidence of deep-vein thrombosis after cementless total hip replacement. J Bone Joint Surg Am. 1988;70: Kim YH. The incidence of deep vein thrombosis after cementless and cemented knee replacement. J Bone Joint Surg Br. 1990;72: Ansari S, Warwick D, Ackroyd CE, Newman JH. Incidence of fatal pulmonary embolism after 1,390 knee arthroplasties without routine prophylactic anticoagulation, except in high-risk cases. J Arthroplasty. 1997;12: Doouss TW. The clinical significance of venous thrombosis of the calf. Br J Surg. 1976;63: Fong YK, Ruban P, Yeo SJ, Lee BP, Lo NN, Seow KH, Ng SC. Use of low molecular weight heparin for prevention of deep vein thrombosis in total knee arthroplasty a study of its efficacy in an Asian population. Ann Acad Med Singapore. 2000;29: Francis CW, Ricotta JJ, Evarts CM, Marder VJ. Long-term clinical observations and venous functional abnormalities after asymptomatic venous thrombosis following total hip or knee arthroplasty. Clin Orthop. 1988;232: Giachino A. Relationship between deep-vein thrombosis in the calf and fatal pulmonary embolism. Can J Surg. 1988;31: Lotke PA, Ecker ML, Alavi A, Berkowitz H. Indications for the treatment of deep venous thrombosis following total knee replacement. J Bone Joint Surg Am. 1984;66: Miric A, Lombardi P, Sculco TP. Deep vein thrombosis prophylaxis: a comprehensive approach for total hip and total knee arthroplasty patient populations. Am J Orthop. 2000;29: Sculco TP. Establishing a universal protocol for deep vein thrombosis following orthopedic surgery: total knee arthroplasty. Orthopedics. 1996;19 Suppl: Stulberg BN, Insall JN, Williams GW, Ghelman B. Deep-vein thrombosis following total knee replacement. An analysis of six hundred and thirty-eight arthroplasties. J Bone Joint Surg Am. 1984;66: Colwell CW Jr. Low molecular weight heparin prophylaxis in total knee arthroplasty: the answer. Clin Orthop. 2001;392:245-8.
Incidence of post-operative deep vein thrombosis in patients undergoing joint replacement surgeries of lower limb
2017; 3(3): 140-144 ISSN: 2395-1958 IJOS 2017; 3(3): 140-144 2017 IJOS www.orthopaper.com Received: 11-05-2017 Accepted: 12-06-2017 Dr. Nachiketan K Dore Senior Resident, Dept. of Orthopedics, ESICMC and
More informationAre There Clinical Meaning on Asymptomatic Pulmonary Embolism After Total Knee Arthroplasty?
Are There Clinical Meaning on Asymptomatic Pulmonary Embolism After Total Knee Arthroplasty? * 1,2 ATSUSHI SATO, MD, PhD, * 1,2 Takayuki Koya, * 2,3 Hiroshi Takagi, * 2 Jun Oike,, * 2 Saki Yagura, * 2
More informationEpidemiology of Venous Thromboembolism in the East. Heng Joo NG Department of Haematology Singapore General Hospital Singapore
Epidemiology of Venous Thromboembolism in the East Heng Joo NG Department of Haematology Singapore General Hospital Singapore Early Literature Tinckler LF Br Med J 1964;1:502 Propagating a notion.. Hwang
More informationProphylaxis for Venous Thromboembolism Following Total Knee Arthroplasty: A Survey of Korean Knee Surgeons
Original Article Knee Surg Relat Res 2016;28(3):207-212 http://dx.doi.org/10.5792/ksrr.2016.28.3.207 pissn 2234-0726 eissn 2234-2451 Knee Surgery & Related Research Prophylaxis for Venous Thromboembolism
More informationDeep venous thrombosis (DVT) occurs frequently
Ann Vasc Dis Vol.5, No.3; 2012; pp 328 333 2012 Annals of Vascular Diseases doi: 10.3400/avd.oa.12.00049 Original Article Deep Vein Thrombosis in Orthopedic Surgery of the Lower Extremities Masatoshi Motohashi,
More informationJapanese Deep Vein Thrombosis
Japanese Deep Vein Thrombosis and Pulmonary Embolism after Total Knee Arthroplasty Artificial joint and cartilage implantation center, Kitasato institute hospital, Kitasato university Yasunori Tsukimura
More informationEarly Ambulation Reduces the Risk of Venous Thromboembolism After Total Knee Replacement. Marilyn Szekendi, PhD, RN
Early Ambulation Reduces the Risk of Venous Thromboembolism After Total Knee Replacement Marilyn Szekendi, PhD, RN ANA 7 th Annual Nursing Quality Conference, February 2013 Research Team Banafsheh Sadeghi,
More informationCheng-Ta Wu 1, Bradley Chen 2, Jun-Wen Wang 1,3*, Shih-Hsiang Yen 1 and Chung-Cheng Huang 4
Wu et al. Journal of Orthopaedic Surgery and Research (2018) 13:173 https://doi.org/10.1186/s13018-018-0883-1 RESEARCH ARTICLE Open Access Plasma D-dimer is not useful in the prediction of deep vein thrombosis
More informationCURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM. Gordon Lowe Professor of Vascular Medicine University of Glasgow
CURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM Gordon Lowe Professor of Vascular Medicine University of Glasgow VENOUS THROMBOEMBOLISM Common cause of death and disability 50% hospital-acquired
More informationReducing the risk of venous thrombo-embolism (VTE) in hospital and after discharge
Reducing the risk of venous thrombo-embolism (VTE) in hospital and after discharge What is a venous thromboembolism (VTE)? This is a medical term that describes a blood clot that develops in a deep vein
More informationDeep Vein Thrombosis and Pulmonary Embolism in the Perioperative Patient
...PRESENTATIONS... Deep Vein Thrombosis and Pulmonary Embolism in the Perioperative Patient Based on a presentation by James E. Muntz, MD Presentation Summary Approximately 500,000 cases of deep vein
More informationIncidence of Venous Thromboembolism After Arthroscopic Anterior Cruciate Ligament Reconstruction
Incidence of Venous Thromboembolism After Arthroscopic Anterior Cruciate Ligament Reconstruction Masaki Nagashima 1,2 Toshiro Otani 3 Hiroyuki Seki 1,2 Kenichiro Takeshima 2 Nobuto Origuchi 4 Ken Ishii
More informationSymptomatic Venous Thromboembolism after Total Hip/Knee Replacement: A Population-based Taiwan Study
IMPROVING PATIENT SAFETY Preventing & Managing Venous Thromboembolism Session 8 Data Driving Strategies for VTE Prevention and Management 3/30/2012; 15.35-15.55 Symptomatic Venous Thromboembolism after
More informationSlide 1. Slide 2. Slide 3. Outline of This Presentation
Slide 1 Current Approaches to Venous Thromboembolism Prevention in Orthopedic Patients Hujefa Vora, MD Maria Fox, RN June 9, 2017 Slide 2 Slide 3 Outline of This Presentation Pathophysiology of venous
More informationVenous thrombosis is common and often occurs spontaneously, but it also frequently accompanies medical and surgical conditions, both in the community
Venous Thrombosis Venous Thrombosis It occurs mainly in the deep veins of the leg (deep vein thrombosis, DVT), from which parts of the clot frequently embolize to the lungs (pulmonary embolism, PE). Fewer
More informationDiagnosis and Treatment of Deep Venous Thrombosis and Pulmonary Embolism
Agency for Healthcare Research and Quality Evidence Report/Technology Assessment Diagnosis and Treatment of Deep Venous Thrombosis and Pulmonary Embolism Summary Number 68 Overview Venous thromboembolism
More informationVenous Thromboembolism Prophylaxis After Major Orthopaedic Surgery: A Pooled Analysis of Randomized Controlled Trials
Winner of the AAHKS Award Venous Thromboembolism Prophylaxis After Major Orthopaedic Surgery: A Pooled Analysis of Randomized Controlled Trials Greg A. Brown, MD, PhD The Journal of Arthroplasty Vol. 24
More informationPrimary VTE Prophylaxis. Ponlapat Rojnuckarin, MD PhD Chulalongkorn University Bangkok, Thailand
Primary VTE Prophylaxis Ponlapat Rojnuckarin, MD PhD Chulalongkorn University Bangkok, Thailand A 70-yr-old female before THA BMI 31 kg/m 2 with varicose vein What do you recommend for VTE prevention?
More informationThe incidence of deep venous thrombosis patients undergoing abdominal aortic aneurysm resection
The incidence of deep venous thrombosis patients undergoing abdominal aortic aneurysm resection in Jeffrey W. Olin, DO, Robert A. Graor, MD, Patrick O'Hara, MD, and Jess R. Young, MD, Cleveland, Ohio Purpose:
More informationAdam Goldfarb, M.A., D.C., D.E.S.S. Introduction
Venous Thromboembolism Prophylaxis following Lower Extremity Orthopedic Surgery: A Review of the Biomedical Research Literature and Evidence-Based Policy in the United States. Adam Goldfarb, M.A., D.C.,
More informationPage: 1 of 13. Post-Surgical Outpatient Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis
Last Review Status/Date: March 2014 Page: 1 of 13 Compression Devices for Venous Description Patients undergoing major orthopedic surgery are at increased risk for venous thromboembolism (VTE). Patients
More informationClinical Practice Guideline for Patients Requiring Total Hip Replacement
Clinical Practice Guideline for Patients Requiring Total Hip Replacement Inclusions Patients undergoing elective total hip replacement Exclusions Patients with active local or systemic infection or medical
More informationNOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.
TITLE VENOUS THROMBOEMBOLISM PROPHYLAXIS SCOPE Provincial Acute and Sub-Acute Care Facilities APPROVAL AUTHORITY Alberta Health Services Executive Committee SPONSOR Vice President, Quality and Chief Medical
More informationThese are guidelines only and can be deviated from if it is thought to be in the patient s best interest.
Clinical Guideline Venothromboembolism prophylaxis: Trauma and Orthopaedics Venous thromboembolism (VTE) is a recognised complication associated with inactivity and surgical procedures. Therefore, all
More informationAnticoagulation for prevention of venous thromboembolism
Anticoagulation for prevention of venous thromboembolism Original article by: Michael Tam Note: updated in June 2009 with the eighth edition (from the seventh) evidence-based clinical practice guidelines
More informationManagement of Post-Thrombotic Syndrome
Management of Post-Thrombotic Syndrome Thanainit Chotanaphuti Phramongkutklao College of Medicine Bangkok, Thailand President of CAOS Asia President of Thai Hip & Knee Society President of ASEAN Arthroplasty
More informationDeep venous thrombosis and pulmonary embolism in joint replacement surgery
Deep venous thrombosis and pulmonary embolism in joint replacement surgery Even though joint replacement surgery is an effective procedure and in expert hands yields a low complication rate, deep venous
More informationJessica Bryan, Natalia Evans, Karlyn Henderson, & Whitney Parks
Jessica Bryan, Natalia Evans, Karlyn Henderson, & Whitney Parks 1. What is the most common cause of death in hospitalized patients? 1. Hospital-acquired infection 2. Pulmonary embolism 3. Myocardial infarction
More informationIncidence of Post-Operative Venous Thromboembolism Using Compression Ultrasonography Following Trauma to Spine and Long Bones of Lower Extremity
Open Journal of Orthopedics, 2013, 3, 97-101 http://dx.doi.org/10.4236/ojo.2013.32019 Published Online June 2013 (http://www.scirp.org/journal/ojo) 97 Incidence of Post-Operative Venous Thromboembolism
More informationScreening for proximal deep venous thrombosis using B-mode venous ultrasonography following major hip surgery: implications for clinical management
Division of Angiology and Hemostasis 1, Medical Clinic I 2, Clinic of Orthopedic Surgery 3, Departments of Medicine and Surgery, University Hospital of Geneva, 1211 Geneva 14 Submitted 25. 5. 94/Accepted
More informationAnesthesia for Total Hip and Knee Arthroplasty
Anesthesia for Total Hip and Knee Arthroplasty Typical approach Describe anesthesia technique Rather Describe issues with THA and TKA How anesthesia can modify Issues Total Hip Total Knee Blood Loss ++
More informationIncidence of deep vein thrombosis after major spine surgeries with no mechanical or chemical prophylaxis
29 29 33 Incidence of deep vein thrombosis after major spine surgeries with no mechanical or chemical prophylaxis Author Institution Sreedharan Namboothiri Kovai Medical Center and Hospitals, Coimbatore,
More informationDVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE)
DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE) Introduction VTE (DVT/PE) is an important complication in hospitalized patients Hospitalization for acute medical illness
More informationAJO. An Original Study. Ashley Levack, MAS, Atul F. Kamath, MD, and Jess H. Lonner, MD
An Original Study Ashley Levack, MAS, Atul F. Kamath, MD, and Jess H. Lonner, MD dvances in surgical technique, patient selection, and prosthetic design for patellofemoral arthroplasty (PFA) have generated
More informationComparison of high-flex and conventional implants for bilateral total knee arthroplasty
ISPUB.COM The Internet Journal of Orthopedic Surgery Volume 14 Number 1 Comparison of high-flex and conventional implants for bilateral total knee arthroplasty C Martin-Hernandez, M Guillen-Soriano, A
More informationObjectives. Venous Thromboembolism (VTE) Prophylaxis. Case VTE WHY DO IT? Question: Who Is At Risk?
Objectives Venous Thromboembolism (VTE) Prophylaxis Rishi Garg, MD Department of Medicine Identify patients at risk for VTE Options for VTE prophylaxis Current Recommendations (based on The Seventh ACCP
More informationThe optimal regime of antithrombotic prophylaxis
Prevention of deep-vein thrombosis after total knee replacement RANDOMISED COMPARISON BETWEEN A LOW-MOLECULAR-WEIGHT HEPARIN (NADROPARIN) AND MECHANICAL PROPHYLAXIS WITH A FOOT-PUMP SYSTEM J. Blanchard,
More informationVenous Thromboembolism. Prevention
Venous Thromboembolism Prevention August 2010 Venous Thromboembloism Prevention 1 1 Expected Practice Assess all patients upon admission to the ICU for risk factors of venous thromboembolism (VTE) and
More informationVenothromboembolism prophylaxis: Trauma and Orthopaedics Clinical guideline, V2
Clinical Guideline Venothromboembolism prophylaxis: Trauma and Orthopaedics 11/11/11 TEMPORARY GUIDANCE There is no prophylactic tinzaparin available in the Trust currently. Please substitute enoxaparin
More informationDEEP -VEIN THROMBOSIS FOLLOWING HIP SURGERY FOR FRACTURE OF THE PROXIMAL FEMUR A K Mitra, T K Khoo, C C L Ngan
DEEP -VEIN THROMBOSIS FOLLOWING HIP SURGERY FOR FRACTURE OF THE PROXIMAL FEMUR A K Mitra, T K Khoo, C C L Ngan ABSTRACT This is a prospective study involving seventy-two consecutive admissions of patients
More informationIJBCP International Journal of Basic & Clinical Pharmacology
Print ISSN: 2319-2003 Online ISSN: 2279-0780 IJBCP International Journal of Basic & Clinical Pharmacology doi: 10.5455/2319-2003.ijbcp20130819 Research Article The use of routine chemoprophylaxis for deep
More informationProtocol. Postsurgical Outpatient Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis
Postsurgical Outpatient Use of Limb Compression Devices for (10128) (Formerly Outpatient Use of Limb Pneumatic Compression Devices for ) Medical Benefit Effective Date: 07/01/14 Next Review Date: 03/15
More informationWhat evidence exists that describes the efficacy of mechanical prophylaxis for venous thromboembolism (VTE) in adult surgical patients?
July 2015 Rapid Review Evidence Summary McGill University Health Centre: Division of Nursing Research and MUHC Libraries What evidence exists that describes the efficacy of mechanical prophylaxis for venous
More informationPage: 1 of 14. Post-Surgical Outpatient Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis
Subject: Post-Surgical Outpatient Use of Limb Page: 1 of 14 Last Review Status/Date: March 2015 Post-Surgical Outpatient Use of Limb Compression Devices for Venous Description Patients undergoing major
More informationNurse Initiated Sequential Compression Device Application Program for Total Knee Replacement Patient
Nurse Initiated Sequential Compression Device Application Program for Total Knee Replacement Patient Cheung Shuk Shan, Susana (APN,O&T, PYNEH) 15 May, 2013 Total Knee Replacement (TKR) TKR is a common
More informationProper Diagnosis of Venous Thromboembolism (VTE)
Proper Diagnosis of Venous Thromboembolism (VTE) Whal Lee, M.D. Seoul National University Hospital Department of Radiology 2 nd EFORT Asia Symposium, 3 rd November 2010, Taipei DVT - Risk Factors Previous
More informationOral Anticoagulation Drug Class Prior Authorization Protocol
Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationPostsurgical Home Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis
Clinical Position Statement Postsurgical Home Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis Effective: October 2017 Next Review: September 2018 CLINICAL POSITION STATEMENT Postsurgical
More informationIncidence of DVT Post- Hip or Knee Replacement. A Comparison of Incidence at Boundary Trails Health Centre to a Credible Baseline Incidence
Incidence of DVT Post- Hip or Knee Replacement A Comparison of Incidence at Boundary Trails Health Centre to a Credible Baseline Incidence Background DVTs Pulmonary Embolisms Death Symptomatic DVTs (leg
More informationVTE Prevention After Hip or Knee Replacement
This Clinical Resource gives subscribers additional insight related to the Recommendations published in May 2018 ~ Resource #340506 VTE Prevention After Hip or Knee Replacement The American College of
More informationGuideline Quick View: Venous Thromboembolism
Guideline Quick View: Venous Thromboembolism The AORN Guideline Quick View is a key component of Guideline Essentials, a suite of online implementation tools designed to help the perioperative team translate
More informationDeep vein thrombosis and its prevention in critically ill adults Attia J, Ray J G, Cook D J, Douketis J, Ginsberg J S, Geerts W H
Deep vein thrombosis and its prevention in critically ill adults Attia J, Ray J G, Cook D J, Douketis J, Ginsberg J S, Geerts W H Authors' objectives To systematically review the incidence of deep vein
More informationSAFETY OF BILATERAL SINGLE STAGE TOTAL KNEE REPLACEMENT UNDER ONE ANAESTHESIA IN TERMS OF PERIOPERATIVE COMPLICATIONS
IJCRR Vol 05 issue 07 Section: Healthcare Category: Research Received on: 23/01/13 Revised on: 19/02/13 Accepted on: 17/03/13 SAFETY OF BILATERAL SINGLE STAGE TOTAL KNEE REPLACEMENT UNDER ONE ANAESTHESIA
More informationPost-Surgical Outpatient Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis
Post-Surgical Outpatient Use of Limb Compression Devices for Venous Thromboembolism Prophylaxis Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary,
More informationVenous Thromboembolism Prophylaxis
Approved by: Venous Thromboembolism Prophylaxis Vice President and Chief Medical Officer; and Vice President and Chief Operating Officer Corporate Policy & Procedures Manual Number: Date Approved January
More informationDeep Vein Thrombosis and Pulmonary Embolism: Patient Information
Deep Vein Thrombosis and Pulmonary Embolism: Patient Information A Deep Vein Thrombosis (DVT) and a Pulmonary Embolism (PE) are both disorders of unwanted blood clotting. Unwanted blood clots can occur
More informationMisunderstandings of Venous thromboembolism prophylaxis
Misunderstandings of Venous thromboembolism prophylaxis Veerendra Chadachan Senior Consultant Dept of General Medicine (Vascular Medicine and Hypertension) Tan Tock Seng Hospital, Singapore Case scenario
More informationPrevention of Venous Thromboembolism
Prevention of Venous Thromboembolism Surgical Care Improvement Project Dale W. Bratzler, DO, MPH President and CEO Dale W. Bratzler, DO, MPH Oklahoma Foundation for Medical Quality QIOSC Medical Director
More informationTRANSPARENCY COMMITTEE OPINION. 18 April 2007
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 April 2007 ARIXTRA 2.5 mg/0.5 ml, solution for injection in prefilled syringe Pack of 2 (CIP: 359 225-4) Pack of
More informationPatients who undergo total knee replacement (TKR)
A randomised comparison of a foot pump and low-molecular-weight heparin in the prevention of deep-vein thrombosis after total knee replacement D. Warwick, J. Harrison, S. Whitehouse, A. Mitchelmore, M.
More informationIndividualizing VTE Treatment and Prevention of Recurrence: The Place for Direct Oral Anticoagulants in VTE
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationWhat You Should Know
1 New 2018 ASH Clinical Practice Guidelines on Venous Thromboembolism: What You Should Know New 2018 ASH Clinical Practice Guidelines on Venous Thromboembolism: What You Should Know The American Society
More information2/22/2018. Goals. What are We Concerned About?
DVT Prophylaxis - Concerns in Foot and Ankle Pathology CSFA Tampa, Feb. 2018 STEVEN STEINLAUF, MD THE ORTHOPAEDIC FOOT AND ANKLE INSTITUTE OF SOUTH FLORIDA CLINICAL ASSISTANT PROFESSOR THE UNIVERSITY OF
More informationGeneral. Recommendations. Guideline Title. Bibliographic Source(s) Guideline Status. Major Recommendations
General Guideline Title Prevention of deep vein thrombosis and pulmonary embolism. Bibliographic Source(s) American College of Obstetricians and Gynecologists (ACOG). Prevention of deep vein thrombosis
More informationNOTE: Deep Vein Thrombosis (DVT) Risk Factors
Deep Vein Thrombosis (DVT) Deep Vein Thrombosis (DVT) is the formation of a blood clot, known as a thrombus, in the deep leg vein. It is a very serious condition that can cause permanent damage to the
More informationIn the Clinic: Annals Sweta Kakaraparthi 1/23/15
In the Clinic: Annals Sweta Kakaraparthi 1/23/15 Case Scenerio 56 year old female with breast cancer presents to the clinic for her 3 month followup! She is concerned about blood clots and asks you about
More informationGENERAL SURGICAL ADULT POST-OPERATIVE ORDERS 1 of 4
down ADULT POST-OPERATIVE 1 of 4 9 Actual 9 Estimated Patient ID Area Weight kg 9 Actual 9 Estimated Height cm ALLERGIES: REFER TO ALLERGY PROFILE/ POWERCHART Admit to: Post Anesthesia Care Unit (PACU),
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 16 December 1999 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON CLINICAL
More informationDeep Vein Thrombosis and Pulmonary Embolism
Page 1 of 12 PATIENT EDUCATION Deep Vein Thrombosis and Pulmonary Embolism Take Steps to Prevent DVTs and PEs Deep vein thrombosis and pulmonary embolism are serious conditions that can affect people of
More informationIncidence of Symptomatic Pulmonary Embolism in Spinal Surgery
Incidence of Symptomatic Pulmonary Embolism in Spinal Surgery Chatupon Chotigavanichaya MD*, Monchai Ruangchainikom MD*, Choompon Piyavanno MD*, Ekkapoj Korwutthikulrangsri MD*, Sirichai Wilartratsami
More informationTo prevent blood clots after hip or knee replacement surgery This booklet contains information for those who have been prescribed ELIQUIS (apixaban)
To prevent blood clots after hip or knee replacement surgery This booklet contains information for those who have been prescribed ELIQUIS (apixaban) after hip or knee replacement surgery Always read the
More informationBath, Philip M.W. and England, Timothy J. (2009) Thighlength compression stockings and DVT after stroke. Lancet. ISSN (In Press)
Bath, Philip M.W. and England, Timothy J. (2009) Thighlength compression stockings and DVT after stroke. Lancet. ISSN 0140-6736 (In Press) Access from the University of Nottingham repository: http://eprints.nottingham.ac.uk/1087/1/lancet_clots_1_20090522_4.pdf
More informationFatal P.E. Historic 1-2% Current %
Dr. (Prof.) Anil Arora MS (Ortho) DNB (Ortho) Dip SIROT (USA) FAPOA (Korea), FIGOF (Germany), FJOA (Japan) Commonwealth Fellow Joint Replacement (Royal National Orthopaedic Hospital, London, UK) Senior
More informationDeep Vein Thrombosis
Deep Vein Thrombosis Introduction Deep vein thrombosis (DVT) is a blood clot in a vein. This condition can affect men and women of any age and race. DVT is a potentially serious condition. If not treated,
More informationA 25 year old Chinese male school teacher was admitted to this hospital on the 5th of February 1974 with a one day history of swelling SYNOPSIS
307 SINGAPORE MEDICAL JOURNAL Vol. 16, No.4. December, 1975. ILIO -FEMORAL VENOUS THROMBOSIS IN HEALTHY ADULTS By T. Ramanathan, N. K. Yong, F. Wang and T. G. Loh SYNOPSIS 3 cases of ilio -femoral venous
More informationDavid S. Feldman, Joseph D. Zuckerman, Ian Walters, and Stephan R. Sakales
Journal of Orthopaedic Trauma Vol. 7. No.1. pp. 1-5 Ci 1993 Raven Press. Ltd., New York David S. Feldman, Joseph D. Zuckerman, Ian Walters, and Stephan R. Sakales Department of Orthopedic Surgery, Orthopedic
More informationPrevention and management of deep venous thrombosis (DVT) John Fletcher Wound Care Association of New South Wales
Prevention and management of deep venous thrombosis (DVT) John Fletcher Wound Care Association of New South Wales Merimbula, 6 th November 2010 University of Sydney Department of Surgery Westmead Hospital
More informationOrthopaedic Mortality
Orthopaedic Mortality Lessons from VASM Nigel Broughton Orthopaedic Surgeon, Peninsula Health AOA Rep on VASM Colin Russell Founder of VASM Director of Surgery, Peninsula Health 1993-2007 First Clinical
More informationMabel Labrada, MD Miami VA Medical Center
Mabel Labrada, MD Miami VA Medical Center *1-Treatment for acute DVT with underlying malignancy is for 3 months. *2-Treatment of provoked acute proximal DVT can be stopped after 3months of treatment and
More informationKey words: cardiac rehabilitation; coronary bypass; deep vein thrombosis; prevention; prophylaxis
Deep Vein Thrombosis Among Patients Entering Cardiac Rehabilitation After Coronary Artery Bypass Surgery* Marco Ambrosetti, MD; Mario Salerno, MD; Mara Zambelli, MD; Filippo Mastropasqua, MD; Roberto Tramarin,
More informationOrthopaedic Surgery. Elective Total Hip Replacement
Orthopaedic Surgery Elective Total Hip Replacement The Department of Orthopaedics offers specialist medical and surgical treatments on musculoskeletal disorders, joint replacements, foot and ankle disorders,
More informationAbbreviations: ACCP American College of Chest Physicians; CI confidence interval; CPMP Committee for Proprietary Medicinal Products
Superiority of Fondaparinux Over Enoxaparin in Preventing Venous Thromboembolism in Major Orthopedic Surgery Using Different Efficacy End Points* Alexander G.G. Turpie, MD; Kenneth A. Bauer, MD; Bengt
More information*Corresponding Author:
Audit of venous thromboembolism prophylaxis administered to general surgical patients undergoing elective and emergency operations at National Hospital, Sri Lanka *Migara Seneviratne 1, Asanka Hemachandra
More informationBilateral total knee arthroplasty: One mobile-bearing and one fixed-bearing
Journal of Orthopaedic Surgery 2001, 9(1): 45 50 Bilateral total knee arthroplasty: One mobile-bearing and one fixed-bearing KY Chiu, TP Ng, WM Tang and P Lam Department of Orthopaedic Surgery, The University
More informationTITLE: Acetylsalicylic Acid for Venous Thromboembolism Prophylaxis: A Review of Clinical Evidence, Benefits and Harms
TITLE: Acetylsalicylic Acid for Venous Thromboembolism Prophylaxis: A Review of Clinical Evidence, Benefits and Harms DATE: 23 August 2011 CONTEXT AND POLICY ISSUES: Thromboembolism occurs when a blood
More informationDOPPLER ULTRASOUND OF DEEP VENOUS THROMBOSIS
TOKUDA HOSPITAL SOFIA DOPPLER ULTRASOUND OF DEEP VENOUS THROMBOSIS MILENA STANEVA, MD, PhD Department of vascular surgery and angiology Venous thromboembolic disease continues to cause significant morbidity
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationSupplementary Online Content
Supplementary Online Content Mismetti P, Laporte S, Pellerin O, Ennezat P-V, Couturaud F, Elias A, et al. Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone
More informationVenous Thromboembolism National Hospital Inpatient Quality Measures
Venous Thromboembolism National Hospital Inpatient Quality Measures Presentation Overview Review venous thromboembolism as a new mandatory measure set Outline measures with exclusions and documentation
More informationORIGINAL INVESTIGATION. Incidence and Time Course of Thromboembolic Outcomes Following Total Hip or Knee Arthroplasty
ORIGINAL INVESTIGATION Incidence and Time Course of Thromboembolic Outcomes Following or Knee Arthroplasty Richard H. White, MD; Patrick S. Romano, MD, MPH; Hong Zhou, PhD; Juan Rodrigo, MD; William Bargar,
More informationResults from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY
Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE Results from
More informationSlide 1: Perioperative Management of Anticoagulation
Perioperative Management of Anticoagulation by Steven L. Cohn, MD, FACP Director, Medical Consultation Service, Kings County Hospital Center, Clinical Professor of Medicine, SUNY Downstate, Brooklyn, NY
More informationVenous Thrombosis in Asia
Venous Thrombosis in Asia Pantep Angchaisuksiri, M.D. Professor of Medicine, Mahidol University, Thailand Adjunct Associate Professor, University of North Carolina, Chapel Hill, USA Venous Thromboembolism
More informationEmbolic Complications of Calf Thrombosis Following Total Hip Arthroplasty
The Journal of Arthroplasty Vol. 8 No. 5 1993 Embolic Complications of Calf Thrombosis Following Total Hip Arthroplasty Vincent D. Pellegrini, Jr, MD,* Mark J. Langhans, MD,-t- Saara Totterman, MD, PhD,:I:
More informationIncidence and management of pulmonary embolism following spinal surgery occurring while under chemical thromboprophylaxis
Eur Spine J (2008) 17:970 974 DOI 10.1007/s00586-008-0668-z ORIGINAL ARTICLE Incidence and management of pulmonary embolism following spinal surgery occurring while under chemical thromboprophylaxis C.
More informationPerioperative VTE Prophylaxis
Perioperative VTE Prophylaxis Gregory J. Misky, M.D. Assistant Professor of Medicine University Of Colorado Denver You recommend the following 72 y.o. man admitted for an elective R hip repair. Patient
More informationH.P. Teng, Y.J. Chou, L.C. Lin, and C.Y. Wong Under general or spinal anesthesia, the knee was flexed gently. In the cases of limited ROM, gentle and
THE BENEFIT OF ARTHROSCOPY FOR SYMPTOMATIC TOTAL KNEE ARTHROPLASTY Hsiu-Peng Teng, Yi-Jiun Chou, Li-Chun Lin, and Chi-Yin Wong Department of Orthopedic Surgery, Kaohsiung Veterans General Hospital, Kaohsiung,
More informationPulmonary Thromboembolism
Pulmonary Thromboembolism James Allen, MD Epidemiology of Pulmonary Embolism 1,500,000 new cases per year in the United States Often asymptomatic 300,000 deaths per year DVT or PE present in 10% of ICU
More informationRisk Factors for Clinically Relevant Pulmonary Embolism and Deep Venous Thrombosis in Patients Undergoing Primary Hip or Knee Arthroplasty
Anesthesiology 2003; 99:552 60 2003 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Risk Factors for Clinically Relevant Pulmonary Embolism and Deep Venous Thrombosis in
More informationRISKS AND COMPLICATIONS
PATIENT INFORMATION SHEET RISKS AND COMPLICATIONS TOTAL HIP REPLACEMENT Page 1 of 8 INTRODUCTION A hip replacement is an extremely successful operation. At least 95% of patients are satisfied with their
More information